Market Overview

New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma — Factors of Influence, Major Initiatives and Sustained Production

Share:

NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Talend S.A. (NASDAQ:TLND), Chipmos Technologies Ltd. (NASDAQ:IMOS), POSCO (NYSE:PKX), Horizon Pharma Public Limited Company (NASDAQ:HZNP), BioSpecifics Technologies Corp (NASDAQ:BSTC), and Arbutus Biopharma Corporation (NASDAQ:ABUS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

TLND DOWNLOAD: http://Fundamental-Markets.com/register/?so=TLND
IMOS DOWNLOAD:
http://Fundamental-Markets.com/register/?so=IMOS
PKX DOWNLOAD:
http://Fundamental-Markets.com/register/?so=PKX
HZNP DOWNLOAD:
http://Fundamental-Markets.com/register/?so=HZNP
BSTC DOWNLOAD:
http://Fundamental-Markets.com/register/?so=BSTC
ABUS DOWNLOAD:
http://Fundamental-Markets.com/register/?so=ABUS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Talend S.A. (NASDAQ:TLND), Chipmos Technologies Ltd. (NASDAQ:IMOS), POSCO (NYSE:PKX), Horizon Pharma Public Limited Company (NASDAQ:HZNP), BioSpecifics Technologies Corp (NASDAQ:BSTC), and Arbutus Biopharma Corporation (NASDAQ:ABUS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 9th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

TALEND S.A. (TLND) REPORT OVERVIEW

Talend S.A's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Talend S.A reported revenue of $41.52MM vs $30.46MM (up 36.32%) and basic earnings per share -$0.37 vs $1.98. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Talend S.A reported revenue of $148.60MM vs $105.98MM (up 40.21%) and basic earnings per share -$1.08 vs -$1.68. Talend S.A is expected to report earnings on May 10th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.19. The estimated EPS forecast for the next fiscal year is -$0.64 and is expected to report on February 12th, 2019.

To read the full Talend S.A. (TLND) report, download it here: http://Fundamental-Markets.com/register/?so=TLND

-----------------------------------------

CHIPMOS TECHNOLOGIES LTD. (IMOS) REPORT OVERVIEW

Chipmos Technologies' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Chipmos Technologies reported revenue of $146.10MM vs $157.20MM (down 7.06%) and basic earnings per share $0.13 vs $0.20 (down 35.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Chipmos Technologies reported revenue of $605.30MM vs $567.52MM (up 6.66%) and basic earnings per share $2.41 vs $1.01 (up 138.61%). Chipmos Technologies is expected to report earnings on May 10th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.38.

To read the full Chipmos Technologies Ltd. (IMOS) report, download it here: http://Fundamental-Markets.com/register/?so=IMOS

-----------------------------------------

POSCO (PKX) REPORT OVERVIEW

POSCO's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, POSCO reported revenue of $13,532.51MM vs $5,495.87MM (up 146.23%) and basic earnings per share $2.45 vs $1.61 (up 52.32%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, POSCO reported revenue of $54,589.59MM vs $47,645.79MM (up 14.57%) and basic earnings per share $7.85 vs $3.72 (up 111.11%). POSCO is expected to report earnings on May 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $2.26. The estimated EPS forecast for the next fiscal year is $9.62 and is expected to report on April 6th, 2018.

To read the full POSCO (PKX) report, download it here: http://Fundamental-Markets.com/register/?so=PKX

-----------------------------------------

HORIZON PHARMA PUBLIC LIMITED COMPANY (HZNP) REPORT OVERVIEW

Horizon Pharma Public's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Horizon Pharma Public reported revenue of $274.22MM vs $310.35MM (down 11.64%) and basic earnings per share -$0.28 vs -$0.81. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Horizon Pharma Public reported revenue of $1,056.23MM vs $981.12MM (up 7.66%) and basic earnings per share -$2.52 vs -$1.04. Horizon Pharma Public is expected to report earnings on May 9th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.21. The estimated EPS forecast for the next fiscal year is $1.77 and is expected to report on February 27th, 2019.

To read the full Horizon Pharma Public Limited Company (HZNP) report, download it here: http://Fundamental-Markets.com/register/?so=HZNP

-----------------------------------------

BIOSPECIFICS TECHNOLOGIES CORP (BSTC) REPORT OVERVIEW

BioSpecifics Technologies' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, BioSpecifics Technologies reported revenue of $6.70MM vs $6.62MM (up 1.22%) and basic earnings per share $0.36 vs $0.41 (down 12.20%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, BioSpecifics Technologies reported revenue of $27.44MM vs $26.25MM (up 4.54%) and basic earnings per share $1.58 vs $1.61 (down 1.86%). BioSpecifics Technologies is expected to report earnings on May 9th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.46.

To read the full BioSpecifics Technologies Corp (BSTC) report, download it here: http://Fundamental-Markets.com/register/?so=BSTC

-----------------------------------------

ARBUTUS BIOPHARMA CORPORATION (ABUS) REPORT OVERVIEW

Arbutus Biopharma's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Arbutus Biopharma reported revenue of $2.53MM vs -$0.20MM and basic earnings per share -$0.68 vs -$4.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Arbutus Biopharma reported revenue of $10.70MM vs $1.49MM (up 617.64%) and basic earnings per share -$1.56 vs -$7.24. Arbutus Biopharma is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.34. The estimated EPS forecast for the next fiscal year is -$1.65 and is expected to report on March 13th, 2019.

To read the full Arbutus Biopharma Corporation (ABUS) report, download it here: http://Fundamental-Markets.com/register/?so=ABUS

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!